Vote Scores
Filings read through

Coherus BioSciences, Inc.: how funds voted at the meeting of 11 Jun 2025

Meeting
Season
year to 30 June 2025
Filers reporting
165
Ballot items
5

165 filers on Form N-PX reported votes at the Coherus BioSciences, Inc. meeting of 11 Jun 2025. The records fall into 5 ballot items. The page lists them in ballot order: items of the company first, then proposals from security holders. Each bar shows how the reporting filers split. It is not the result of the meeting.

This meeting is in the year to 30 June 2025. The latest season on file is the year to 30 June 2026. The page of Coherus BioSciences, Inc. has the latest meeting.

If the reporting person has not received confirmation of the actual number of votes cast prior to filing a report on Form N-PX, the numbers reported may reflect the number of shares instructed to be cast. A reporting person is not required to amend a previously filed Form N-PX report if the reporting person subsequently receives confirmation of the actual number of votes cast.

The words of the SEC. Source: Form N-PX and its instructions, Special Instructions D.5 and D.8, copied on .

The words of this site: the filer writes each filing. The SEC does not say that it checked the votes. A lender does not vote shares that are on loan. A later filing (Form N-PX/A) can replace an earlier filing, and the site uses the latest.

The figures on this page count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting.

The page gives records. It gives no investment advice and no advice on how to vote.

Season on this page: year to 30 June 2025. Filings read through . How the figures are made

The ballot

ForAgainstAbstain, withhold or otherAmber tick: the part cast against management

  1. Item 1: Director elections

    3 nominees. 89.5% of the reported votes are for. 13 filers withheld from or voted against at least one nominee.

    312 vote records from 57 filers. 4 of the 57 filers that marked the item voted against management.

    • Positions of 26 fund families
    • For 24
    • Abstain or withhold 2
    • Against management 2
  2. Item 2: Advisory vote on executive pay (say-on-pay)

    229 vote records from 164 filers. 104 of the 156 filers that marked the item voted against management. 8 filers gave no management mark.

    • Positions of 34 fund families
    • For 10
    • Against 23
    • Split or no vote 1
    • Against management 23
  3. Item 3: Audit-related items (auditor ratification)

    104 vote records from 57 filers. 2 of the 57 filers that marked the item voted against management.

    • Positions of 26 fund families
    • For 26
  4. Item 4: CAPITAL STRUCTURE: management items

    The company's items in this category are shown together, because filers word and number them differently.

    6 vote records from 3 filers. 0 of the 3 filers that marked the item voted against management.

    • Positions of one fund family
    • For 1
  5. Item 5: COMPENSATION: management items

    The company's items in this category are shown together, because filers word and number them differently.

    99 vote records from 55 filers. 2 of the 55 filers that marked the item voted against management.

    • Positions of 25 fund families
    • For 25

Positions of the fund families

A position is not the vote of each fund. The position of a family is the way most of the shares reported by its filers were voted. Funds of one family can vote in different ways.

KeyForAgainstAbstain or withholdSplit or no voteAgainst management

Fund families at Coherus BioSciences, Inc., meeting of 11 Jun 2025Families in name order. "Abstain" includes withhold. "Split" includes no vote. "No report" means that no filer of the family listed the item.
Fund family2. Say-on-pay3. Auditor
AllianceBernsteinAgainst, against managementNo report
BairdAgainst, against managementNo report
BlackRock and iSharesForFor
BNY MellonForNo report
Charles SchwabAgainst, against managementFor
Columbia ThreadneedleAgainst, against managementFor
DWSAgainst, against managementFor
EquitableAgainst, against managementFor
FidelityAgainst, against managementFor
First TrustSplitNo report
Global XAgainst, against managementFor
Goldman SachsAgainst, against managementFor
Guggenheim and RydexAgainst, against managementFor
InvescoAgainst, against managementFor
J.P. MorganForNo report
John Hancock and ManulifeAgainst, against managementFor
Lincoln FinancialForFor
Macquarie and Delaware FundsAgainst, against managementFor
Morgan Stanley, Eaton Vance and CalvertForFor
NationwideForFor
Neuberger BermanAgainst, against managementNo report
Northern Trust and FlexSharesAgainst, against managementFor
Nuveen and TIAAAgainst, against managementFor
Pacific Life fundsForFor
PGIM and PrudentialAgainst, against managementNo report
PrincipalAgainst, against managementNo report
ProShares and ProFundsAgainst, against managementFor
SEIAgainst, against managementFor
State Street and SPDRForFor
T. Rowe PriceAgainst, against managementFor
VanguardForFor
Victory CapitalAgainst, against managementFor
VoyaAgainst, against managementFor
WisdomTreeForFor

Questions

How many filers reported votes at the Coherus BioSciences, Inc. meeting?
165 Form N-PX filers reported votes at the meeting of 11 Jun 2025. On say-on-pay, 104 of 156 filers that marked the item voted against management (66.7%).
Is this the result of the meeting?
No. The page counts the filers that report on Form N-PX, and the shares they reported. Coherus BioSciences, Inc. reports the result of a vote on Form 8-K.
Why does the page show counts only for director elections?
A director record names the nominee. This site has no page and no row about a person. For director elections it keeps the number of nominees and the split of votes.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list Coherus BioSciences, Inc. with a meeting date within three days of 11 Jun 2025. A proposal title is the most common wording among filers. Where a wording can name a person, the SEC category is shown. The filers wrote the filings. Filings read through .